1:00 AM
-
60 mins- CNS/Neurological
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is head ... -
60 mins- CNS/Neurological
NurrOn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company (Boston, USA) dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nur ... -
60 mins- Oncology
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved ... -
60 mins- Oncology
Clinical stage Radiopharmaceutical company with therapeutic and imaging molecules. Currently in Phase 1 and Phase 2. -
60 mins- Oncology
Rakuten Medical, Inc. is a global biotechnology company founded in 2010, dedicated to developing and commercializing precision cell-targeting therapies through our proprietary Alluminox™ platform. All ... -
60 mins- CNS/Neurological
Tonix is a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates. Tonix’s lead program, TNX-102 SL, is a U.S. FDA Fast-Track designated product can ... -
60 mins- Gastrointestinal
Eupraxia Pharmaceuticals is a biotechnology company focused on precision delivery of drugs into disease tissues using its proprietary Diffusphere technology. With its lead program in Eosinophilic Esop ... -
60 mins- Oncology
ImmuneOnco is a HK-listed (HK.1541), clinical stage biotech company focused on discovering and developing immunotherapies to treat cancer and other diseases. The most advanced program is phase III tim ... -
60 mins- Immunology
GeoVax is developing novel vaccines for infectious diseases and therapies for solid tumor cancers. Its lead clinical program is a next-generation COVID-19 vaccine for which GeoVax was awarded a BARDA- ... -
60 mins- Oncology
Greenwich LifeSciences (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating the safety and efficacy of GP2, an immunot ... -
60 mins- Ophthalmology
Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells only in regions of inflammation. Our tar ... -
60 mins- Orphan/Rare Diseases
Protalix is a biopharmaceutical company focused on the development, production, and commercialization of innovative medicines for patients living with rare diseases. We are advancing promising candida ... -
60 mins- Ophthalmology
Epion Therapeutics is developing a minimally -invasive treatment for ectatic corneal disease that can bring early intervention to millions of patients globally. Our EpiSmart approach is a transformat ... -
60 mins- Multiple Therapeutics
Cellphire Therapeutics is a clinical stage Biotech believes no-one should die from controllable hemorrhage. We are revolutionizing bleeding treatment with platelet derived therapeutics. With a late st ... -
60 mins- CNS/Neurological
PathMaker Neurosystems is a clinical-stage company developing a breakthrough, non-invasive approach to the treatment of ALS (amyotrophic lateral sclerosis), an incurable neurodegenerative disease that ... -
60 mins- Gene/Cell Therapy
Carina Biotech is clinical stage, immuno-oncology company developing CAR-T and other adoptive cell therapies for the treatment of solid cancers. Its lead candidate, CNA3103, targets LGR5 a cancer stem ... -
60 mins- Infectious Diseases
Ziphius is a biotechnology company developing best-in-class vaccines and therapeutics based on its proprietary saRNA and carrier technology (LNP) platform. This platform enables higher and prolonged p ... -
60 mins- Metabolic Diseases
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexi ... -
60 mins- Reproductive/Sexual Health
Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of d ... -
60 mins- Inflammation
Recognizing the link between inflammation and numerous chronic diseases, including Alzheimer’s, cardiovascular disease, cancer, and various disorders of the skin, intestines, and liver, Halia expanded ... -
60 mins- Oncology
Medicovestor, Inc pioneers novel Antibody Drug Conjugate (ADC) platforms to bridge the therapeutic gaps of existing ADCs. It leverages the complementary expertise and extensive experience of each memb ... -
60 mins- Other
Akebia Therapeutics works to develop unique therapeutics that have the potential to set new standards of care for people living with kidney disease. Akebia is a fully integrated biopharmaceutical comp ... -
60 mins- Reproductive/Sexual Health
Vaneltix Pharma, Inc. is a private clinical stage biotech focused on developing pharmaceutical products for the treatment of urologic conditions with high unmet need, with a focus on bladder condition ... -
60 mins- Pain Management
Sustained Therapeutics is a clinical stage company developing non-opioid locally injected therapeutics for the treatment of pain. Our novel sustained-release drug delivery platform has the potential t ... -
60 mins- Orphan/Rare Diseases
BOOST Pharma is a clinical-stage biopharmaceutical company focused on the development of novel cell therapy treatments. The company is currently developing a first-in-class therapy to treat Osteogenes ... -
60 mins- Other
Dimer Pharmaceuticals is a cutting-edge biotech company revolutionizing treatments for cancer and neurodegenerative diseases through its innovative “Oncodegenic Approach.” Epidemiological data reveal ... -
60 mins- CNS/Neurological
Magdalena Biosciences, Inc. has a paradigm shifting drug development approach, 12-24 months from plant collection to clinical POC study initiation possible; de-risk early with higher probability for f ... -
60 mins- Gastrointestinal
Our mission is to restore voluntary bowel and bladder function to patients with neurological conditions such as spinal cord injury or have complications from other diseases such as diabetes, Parkinson ... -
60 mins- Platform for Therapeutics
Seek Labs is developing a programmable rapid response therapeutic platform for target ablation that leverages CRISPR technology. The platform seeks and destroys infectious pathogens and disease-drivin ... -
60 mins- Oncology
TrAMPoline Pharma was founded with a vision to support the next generation of cellular immunotherapies to treat solid tumors. We are developing vectors encoding proprietary co-receptor and signaling p ... -
60 mins- Orphan/Rare Diseases
EveryONE Medicines is committed to developing individualized anti-sense oligonucleotides targeting unique genetic variants causing severe neurodegenerative disease, even if unique to just one person. -
60 mins- Oncology
Radiance is developing next generation Antibody Drug Conjugates and Bispecific ADCs. The Company's lead asset , RB164, an ROR1 ADC, is clinic ready. RB201, is a HER2/TROP2 BsADC, with next generation ... -
.png)
60 mins- Inflammation
Enveda is a biotechnology company aiming to understand and utilize the chemistry that forms the foundation of life. Using their AI-powered tools to identify and characterize the diverse molecules that ... -
60 mins- Immunology
Canopy is an emerging biotech redefining autoimmune therapeutics through its groundbreaking Antigen-Drug Conjugate (AgDC) platform. Backed by leading US-based VCs, the company is led by Dr. Kfir Oved, ... -
60 mins- Platform for Therapeutics
Bound Therapeutics is a pioneering biotechnology company dedicated to the development of RNA-based therapies targeting rare and refractory diseases, with a primary focus on oncology. Our proprietary p ... -
60 mins- CNS/Neurological
Sound Pharma is developing the first drugs to treat hearing loss and tinnitus affecting 50M Americans (the largest CNS/PNS disease). It has advanced its novel small molecule (SPI-1005) through 13 stud ...
10:00 AM
-
50 minsWith the emergence of megarounds in the past year, company leaders are wondering about the prospects for funding if their R&D is not in the most sought after therapeutic areas. Is it still possible to ...
.jpg)
11:00 AM
-
50 minsGLP-1 analogs have changed the game for many people living with obesity, but the medical community is looking for improvements in delivery, side effect profiles and more. This panel will examine how i ...
2:00 PM
-
50 minsA recent McKinsey analysis shows that first-time launches are projected to outnumber those from established companies by nearly two to one. As companies seek to move from the clinic to market, underst ...
3:00 PM
-
50 mins2024 saw a modest uptick compared to the past few years in successful biotech IPOs. In this panel, executives who survived the IPO gauntlet will share the lessons learned during the IPO process and th ...
4:00 PM
-
50 minsThe recent Nobel Prize recognition of AI’s ability to model molecular interactions signals the high expectations for improving drug discovery. However, leading companies are already applying AI tools ...
9:00 AM
-
50 minsWith the election of a new Congress, President, and agency leadership, there are questions about the trajectory of policies and guidelines and what will change for the biotech industry. As new priorit ...
10:00 AM
-
50 minsOncology remains one of the top therapeutic areas garnering investor interest, and scientific advances are yielding new approaches that are showing sometimes game-changing clinical promise in treating ...
11:00 AM
-
50 minsAs venture capital remains difficult to reach, the availability of debt financing, royalty financing, family office funding, and other alternative methods, as well as PIPEs for public companies, becom ...
1:00 PM
-
50 minsThe October 2024 approval of the first schizophrenia drug with a new mechanism of action since the 1950s heralds an acceleration of investment interest in supporting new medicines for neuropsychiatric ...
.jpg)
2:00 PM
-
50 minsJohn Maraganore is a co-founder and executive chair of City Therapeutics. He was the founding CEO and a director of Alnylam Pharmaceuticals - the leading RNAi therapeutics company - which he led for n ...
3:00 PM
-
50 minsDespite an extended period of lower biopharma stock valuations and a start of declining interest rates, M&A totals remain historically low. With a new U.S. government administration taking office, and ...
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}